AMANDA WILHITE: Open Payments
NPI 1124367362 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$70,764 in 192 payments from 10 companies in 2025. Trend: 2023 $36,699 · 2024 $48,772 · 2025 $70,764
Speaker / faculty: $51,226Travel & lodging: $11,763Consulting: $4,146Food & beverage: $2,885Honoraria: $744
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 72 | $43,496 |
| ABBVIE INC. | 71 | $12,576 |
| Lilly USA, LLC | 15 | $8,849 |
| PFIZER INC. | 21 | $4,364 |
| Celltrion USA Inc. | 5 | $1,280 |
| GENZYME CORPORATION | 3 | $85 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| CSL Behring | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: TREMFYA, SKYRIZI, OMVOH, VELSIPITY, STELARA, ZYMFENTRA, RINVOQ, XELJANZ.
Industry payments across TX — which companies pay providers there.
